A Nevada bill targeting the cost of diabetes drugs was stripped of a key provision that would have required drug makers to provide refunds to patients and insurers if wholesale prices rose by more than a medical component of the Consumer Price Index each year.
The move came after the state Legislative Counsel Bureau issued a memo on Monday saying the bill could have violated the Interstate Commerce Clause, which restricts states from regulating interstate commerce, and the Supremacy Clause, which says that federal law supersedes state law when a conflict exists between the two.
About the Author Reprints
